Irbesartan

Drug Profile

Irbesartan

Alternative Names: Aprovel; Avapro; BMS 186295; Irbetan; Karvea; SR 47436; Xarb

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Bristol-Myers Squibb; Sanofi; sanofi-aventis; Shionogi
  • Class Antihypertensives; Biphenyl compounds; Heart failure therapies; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diabetic nephropathies; Hypertension
  • Phase II Atrial fibrillation
  • Discontinued Atherosclerosis

Most Recent Events

  • 31 Mar 2016 Shionogi completes a phase II trial in Atrial fibrillation in Japan (UMIN000005205)
  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
  • 08 Aug 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top